In addition, recombinant FGF19 treatment increased cell proliferation in Huh7, JHH7, HepG2 and PLC/PRF/5 cells (FGF19+FGFR4+ HCC cells and FGF19−FGFR4+ cells). Here, FGFR4 is linked to hepatocellular carcinoma.